StockNews.com Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.

Other analysts have also recently issued research reports about the stock. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Up 1.4 %

REGN stock opened at $903.48 on Tuesday. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm’s 50-day simple moving average is $944.78 and its 200 day simple moving average is $895.25. The stock has a market cap of $99.17 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the company earned $10.96 EPS. The company’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 38.86 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,353,323.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. Insiders sold a total of 10,095 shares of company stock worth $9,664,476 over the last ninety days. 8.83% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. West Paces Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $37,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.